Mutagenic Impurities Risk Assessment Under ICH M7

In pharmaceutical manufacturing, the mutagenic impurities are among the most critical safety concerns. These impurities are responsible for the damage of DNAs, even at trace levels. The damage of genetic material could potentially lead to cancer. Therefore, to manage this risk, regulatory authorities introduced the ICH M7 guideline. These guidelines provide a scientific framework for identifying, evaluating, and controlling mutagenic impurities in drug substances and products. (U.S. Food and Drug Administration)

This blog explains the principles of risk assessment under ICH M7 guidelines. It also illustrates how pharmaceutical chemists can evaluate potential mutagenic impurities during drug development process.

Table of Contents

1. Introduction to Mutagenic Impurities
2. Overview of the ICH M7 Guideline
3. Sources of Mutagenic Impurities in API Synthesis
4. Risk Assessment Workflow Under ICH M7
5. Classification of Mutagenic Impurities
6. Threshold of Toxicological Concern (TTC) Concept
7. Control Strategies for Mutagenic Impurities
8. Practical Examples from Pharmaceutical Manufacturing
9. Critical Challenges in ICH M7 Implementation
10. Conclusion

1. Introduction to Mutagenic Impurities

Mutagenic impurities are chemical compounds that are capable of interacting with DNA and responsible for genetic mutations. If such mutations accumulate in cells, they may lead to carcinogenesis.

During the synthesis of active pharmaceutical ingredients (APIs), several reagents, catalysts, intermediates, and degradation products may generate trace-level impurities. Most impurities are harmless, but DNA-reactive impurities require strict evaluation and control because of their carcinogenic potential. (IntuitionLabs) Regulatory agencies therefore require pharmaceutical companies to perform a systematic risk assessment of mutagenic impurities during drug development and commercialization.

2. Overview of the ICH M7 Guideline

The ICH M7 guideline is titled as below;

“Assessment and Control of DNA-Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk.”

Its primary objective is to ensure that patient exposure to mutagenic impurities. Hence it is recommended that the exposure of these impurities should remains at a level that presents negligible cancer risk. (European Medicines Agency (EMA))

Key features of the guideline include following aspects:

• Identification of potential mutagenic impurities
• Hazard assessment using computational or experimental methods
• Classification of impurities based on mutagenic potential
• Establishment of acceptable intake limits
• Implementation of appropriate control strategies

The above guideline applies to:

• New drug substances
• Drug products during development
• During Post-approval changes that could be affecting impurity profiles

3. Sources of Mutagenic Impurities in API Synthesis

Mutagenic impurities may originate from multiple stages of the synthetic route. Risk assessment therefore begins with a detailed review of the manufacturing process.

Major sources include:

1. Starting materials

Certain starting materials possess structural alerts for mutagenicity.

For example:

• Aromatic amines

2. Reagents and catalysts

Reactive reagents may generate DNA-reactive by-products.

For example:

• Alkyl halides
• Sulfonate esters

3. Reaction by-products

Side reactions can produce mutagenic intermediates.

For example:

• Epoxides
• Nitroso compounds

4. Degradation products

Drug substances may degrade during storage.

For example:

• Nitrosamines formed under oxidative conditions.

5. Process impurities

Impurities introduced during purification or crystallization. A comprehensive impurity list is necessary before any toxicological evaluation.

4. Risk Assessment Workflow Under ICH M7

Risk assessment follows a stepwise scientific workflow.

Step 1: Identification of Potential Impurities

Chemists evaluate the synthetic route and predict possible impurities using:

• Reaction mechanism analysis
• Literature knowledge
• Degradation studies
• Forced degradation experiments

Step 2: Structural Alert Screening

Potential impurities are screened for mutagenicity structural alerts.

For example:

• Nitrosamines
• Alkylating agents
• Epoxides
• Aromatic amines

These alerts indicate possible DNA interaction.

Step 3: In Silico Mutagenicity Prediction

The guideline recommends two complementary (Q)SAR models:

1. Expert rule-based systems
2. Statistical machine learning models

If both models predict mutagenicity, the impurity is treated as a mutagen unless experimental data contradict it. (IntuitionLabs)

Step 4: Experimental Testing for Mutagenic Impurities

If predictions are uncertain, experimental assays may be performed.

Common test:

Ames bacterial reverse mutation assay

This test has been widely used for decades to detect mutagenicity.

Step 5: Determination of Acceptable Limits

Once mutagenicity is established, acceptable exposure limits are defined using the TTC concept or compound-specific toxicological data.

5. Classification of Mutagenic Impurities

ICH M7 divides impurities into five classes based on available data and structural alerts.

Class 1: Known Mutagenic Carcinogens

These compounds are both mutagenic and carcinogenic.

Examples:

• Nitrosamines
• Aflatoxin-like structures

Therefore highy mutagenic impurities require extremely strict control.

Class 2: Known Mutagens with Unknown Carcinogenic Potential

Mutagenicity data exists but carcinogenicity data is lacking.

These compounds must be controlled below the TTC limit.

Class 3: Structural Alerts but No Data

These impurities contain structural features associated with mutagenicity but lack experimental data.

Hence the applied control strategy for these products is:

• Use (Q)SAR prediction
• Conduct Ames testing if necessary

Class 4: Structural Alerts with Evidence of Non-Mutagenicity

Experimental data demonstrate the compound is not mutagenic. After that these impurities are treated as ordinary impurities under ICH Q3A/Q3B guidelines.

Class 5: No Structural Alerts

Compounds with no mutagenic alerts or evidence of mutagenicity. Hence to report these products a standard impurity guidelines can be applied.

In short, the above classification system of the impuririties can help scientists prioritize high-risk impurities.

6. Threshold of Toxicological Concern (TTC)

A central concept in ICH M7 is the Threshold of Toxicological Concern (TTC).

Therefore, the TTC represents an exposure level below which the cancer risk is considered negligible.

For lifetime exposure, the TTC limit is: 1.5 µg/day

This corresponds to an estimated lifetime cancer risk of less than 1 in 100,000 patients. (PMC)

Exposure-Based TTC Limits

Exposure Duration	Acceptable Intake
Lifetime (>10 years)	1.5 µg/day
1–10 years	10 µg/day
1–12 months	20 µg/day
<1 month	120 µg/day

Shorter treatment durations allow higher impurity limits because cumulative exposure is lower.

7. Control Strategies for Mutagenic Impurities

ICH M7 provides four control options to ensure impurity levels remain below acceptable limits.

Option 1: Testing of Final Drug Substance

Routine analytical testing confirms impurity levels remain below limits.

Option 2: Testing of Raw Materials or Intermediates

Upstream testing ensures impurities are removed during processing.

Option 3: Testing plus Process Control

Combination of analytical testing and process control.

Option 4: Process Understanding and Purge Factor

Scientific justification that the manufacturing process removes impurities.

Therefore, this approach relies on:

• Reaction chemistry
• Purification efficiency
• Fate and purge studies

These options provide flexibility for manufacturers while maintaining patient safety.

8. Practical Examples

Example 1: Alkyl Halide Reagent

Alkyl halides are strong electrophiles hence they are capable of DNA alkylation.

Risk assessment approach:

1. Identify alkyl halide reagent
2. Predict potential residual impurity
3. Evaluate purge during crystallization
4. Confirm levels below TTC

Example 2: Nitrosamine Formation

Nitrosamines are potent mutagenic carcinogens.

Some of the most common nitrosamine formation conditions are:

• Secondary amines
• Nitrite sources
• Acidic environment

Hence Control strategies include:

• Removing nitrite sources
• Process redesign
• Sensitive analytical methods (LC-MS/MS).

9. Critical Challenges in ICH M7 Implementation

Despite its clear framework, several challenges remain in the drug development process.

1. Predicting Unknown Impurities

Complex synthetic routes may produce unexpected impurities.

2. Limitations of QSAR Models

Computational predictions may give conflicting results.

Expert toxicological review is often required.

3. Analytical Sensitivity

Detecting impurities at parts-per-billion levels requires highly sensitive analytical methods.

4. Nitrosamine Risk Management

Recent regulatory alerts have increased scrutiny of nitrosamine impurities in pharmaceuticals. Therefore the Pharmaceutical companies must continuously evaluate manufacturing processes.

10. Conclusion

The ICH M7 guideline has transformed the way pharmaceutical scientists evaluate impurity safety. Instead of relying solely on experimental toxicology, the framework integrates process chemistry, computational toxicology, and risk-based regulatory science.

In this context, the key principles include:

• Early identification of potential mutagenic impurities
• Use of predictive toxicology tools
• Application of TTC-based exposure limits
• Implementation of scientifically justified control strategies

For organic chemists working in API synthesis, understanding ICH M7 is essential. Effective risk assessment not only ensures regulatory compliance but also protects patient safety.

As pharmaceutical chemistry continues to evolve, the integration of advanced computational toxicology, predictive modeling, and robust process design will further strengthen impurity risk management.

References

1. ICH Harmonised Guideline M7(R2) – Assessment and Control of DNA Reactive Mutagenic Impurities
   https://www.fda.gov/media/170461/download (U.S. Food and Drug Administration)
2. EMA Scientific Guideline on Mutagenic Impurities
   https://www.ema.europa.eu/en/ich-m7-assessment-control-dna-reactive-mutagenic-impurities-pharmaceuticals-limit-potential-carcinogenic-risk-scientific-guideline (European Medicines Agency (EMA))
3. Honma M. (2025). Risk Assessment of Mutagenic Impurities Using TTC Concept
   https://pmc.ncbi.nlm.nih.gov/articles/PMC12723853/ (PMC)
4. Amberg A. et al. Principles for Implementation of ICH M7
   https://www.sciencedirect.com/science/article/pii/S0273230016300277 (ScienceDirect)
5. Intuition Labs. Overview of ICH M7 and QSAR Approaches
   https://intuitionlabs.ai/articles/ich-m7-mutagenic-impurities-software (IntuitionLabs)

Pharmaceutical impurity solutions offered by SynThink Research Chemicals

We provide pharmaceutical impurity standards to support your method development and drug development projects. We are specialized in the synthesis of pharmacopeial and non-pharmacopeial API impurities. In addition to this, we also have capabilities for custom synthesis of API intermediates and building blocks that are required in the drug development process. In addition to this, we provide the services for the synthesis of small molecules ranging from milligram to gram scale. We deliver each product along with validated analytical data and a Certificate of Analysis. At Synthink we rigorously test the products at regular intervals to confirm their identity and quality. We have expertise in a wide range of products that are categorized as Impurities, Building Blocks, Intermediates, and Nitrosamines. Specifically, we provide various process-related and degradation impurities of sodium-glucose co-transporter 2 (SGLT2) inhibitors like Dapagliflozin, Empagliflozin and Canagliflozin. We are experts in the manufacturing of impurities of cholesterol-lowering drugs such as Atorvastatin, Rosuvastatin andEzetimibe. Also, we offer impurities of the corticosteroid class of APIs, for example, Prednisone, Methylprednisolone, Dexamethasone, and Hydrocortisone.